Birchview Capital’s Aptevo Therapeutics APVO Stock Holding History

Birchview Capital’s Portfolio APVO Stock Details APVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-556	Closed	-$30.5K	–	70
2025 Q2	$30.5K	Buy	+556	New	+$101K	0.03%	68

Other funds holding APVO

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

DRW Securities Chicago, Illinois $4.11B AUM 21.98% 1-Year Est. Return

Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

Focus Partners Wealth Boston, Massachusetts $97.6B AUM 29.43% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Birchview Capital's APVO Position: Q3 2025 in Review

Birchview Capital sold out of Aptevo Therapeutics (APVO) in Q3 2025, closing a stake of 556 shares — an estimated $30.5K sold.

Birchview Capital first reported a position in APVO in Q2 2025 and held it in 1 quarter. The position peaked at $30.5K in Q2 2025. 10 funds tracked by Wall St. Rank hold APVO as of Q3 2025.

Birchview Capital reported no remaining Aptevo Therapeutics position as of Q3 2025 after selling out during the quarter.
Birchview Capital sold 556 Aptevo Therapeutics shares in Q3 2025, an estimated $30.5K.
Birchview Capital first reported a position in Aptevo Therapeutics in Q2 2025 and held it in 1 quarter.
Birchview Capital's Aptevo Therapeutics position peaked at $30.5K in Q2 2025.
10 funds tracked by Wall St. Rank held Aptevo Therapeutics as of Q3 2025.

Based on Birchview Capital's 13F filing for Q3 2025, filed 13 Nov 2025.